04:45 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Solid checkpoint for CARs

PD-L1 family member B7-H3 could put CAR T cells in play for a slew of difficult-to-treat solid tumors, including pediatric cancers that lack targeted therapies, according to a pair of preclinical studies published this year....
05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
23:58 , Apr 19, 2018 |  BC Innovations  |  Product R&D

Automation navigation

Last year’s approvals of the first two CAR T therapies have prompted the field to get serious about industrializing manufacturing of the cells to improve reproducibility and lower costs. While stakeholders agree that automation will...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
20:23 , Jul 28, 2017 |  BC Week In Review  |  Company News

Miltenyi acquires Living Pharma and its CAR T technology

The Lentigen Technology Inc. subsidiary of Miltenyi Biotec GmbH (Bergisch Gladbach, Germany) acquired immunotherapy company Living Pharma Inc. (Baltimore, Md.), gaining Living Pharma’s preclinical Anti-Tag CAR (AT-CAR) engineered T cell therapy technology. The companies will...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Company News

Opus Bio, Miltenyi Biotec deal

Lentigen Corp. changed its name to Opus Bio and sold its lentiviral vector manufacturing business and related assets to Miltenyi, which provides products and services for biomedical research and cellular therapy. The deal includes IP,...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Company News

Miltenyi Biotec, Alfred Mann Institute deal

The institute’s Accellta Ltd. subsidiary granted Miltenyi Biotec non-exclusive, worldwide rights to an Accellta patent for use in Miltenyi’s medium for stem cell cultivation. The partners could not be reached for details. Accellta said it...
07:00 , Jun 10, 2010 |  BC Innovations  |  Tools & Techniques

Predicting allograft tolerance

Based on an analysis of two groups of kidney transplant patients able to thrive without immunosuppressants, consortia in Europe and the U.S. have independently identified immature B cells as markers that could help pinpoint transplant...